Skip to content

Botulinum toxin

Botulinum toxin is a neurotoxin produced by Clostridium botulinum and related species. In medicine, purified preparations are used in carefully controlled doses to reduce cholinergic nerve signaling, most notably at the neuromuscular junction. This pharmacologic effect makes botulinum toxin useful in both therapeutic and aesthetic practice.

The modern botulinum toxin field connects several entity groups:

Botulinum toxin blocks presynaptic release of acetylcholine after internalization into cholinergic nerve terminals. Different serotypes target distinct SNARE proteins, but the shared clinical consequence is temporary chemodenervation. That temporary effect explains the need for repeat treatment cycles rather than permanent correction.

Type A is the dominant serotype in current therapeutic and aesthetic markets because it offers a well-characterized balance of potency, duration, and formulation flexibility. Type B has a narrower but still important role, especially in selected movement disorder settings.

For a concise comparison, see Differences between botulinum toxin types.

Most globally recognized products are based on type A toxin. They differ in manufacturing methods, excipients, complexing proteins, stability, and unit systems. These differences mean units should not be assumed to be interchangeable across brands.

Type B is represented commercially by products such as Myobloc or Neurobloc in some markets.

Botulinum toxin is widely used for conditions involving unwanted muscle contraction, glandular hyperactivity, or selected pain syndromes. Key early topic nodes in this encyclopedia include:

Botulinum toxin is best understood as a structured ecosystem rather than a single drug topic. The toxin type affects biologic behavior, the brand affects formulation and regulatory context, the company affects manufacturing and market presence, and the indication shapes dose, injection pattern, and evidence standards.